Seeking Alpha

WILMINGTON, Mass., Feb. 13, 2014 /PRNewswire/ --  Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it has won an order for its QS-H150 handheld explosives trace detectors (ETD), associated consumables, and services. The total value of the order including consumables and service is expected to be approximately $1,500,000, with the first $1,000,000 to be delivered to the customer during Implant Sciences' fiscal year 2014 for deployment in Latin America.

Hector Giraldo, Managing Director, Americas for Implant Sciences (IMX) commented, "We have been supplying trace detection equipment to Latin America since 2008. Our ETDs are widely used across the region and our reputation for performance was a key factor in winning this contract. The customer also clearly favored our systems' non-radioactive source and non-contact particle sampling technology."

"Latin America is a market which holds great growth potential for us. Hector has done a great job of expanding our presence in the region," added Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones . "Our superior technology, regulatory approvals, and excellent sales and service combine to expand our global footprint."

About the QS-H150 Handheld Explosives Trace Detector

The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and  the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at http://www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation
Company Contact:
Glenn Bolduc, CEO
978-752-1700

or

Investor Contact:
Laurel Moody
646-810-0608

SOURCE Implant Sciences Corporation

Comments (0)
Be the first to comment